WINT WINDTREE THERAPEUT COM USD0.001

0.92
-0.03  -3%
Previous Close 0.95
Open 0.00
Price To book 0.00
Market Cap 8.68M
Shares 9,439,000
Volume 0
Short Ratio 4.41
Av. Daily Volume 215,919

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved March 6, 2012 - under Discovery Laboratories, Inc.
Surfaxin
Respiratory Distress Syndrome
Phase 2b interim safety review completed April 11, 2017. Trial to continue to completion. Top-line data due July 2017.
Aerosurf
Respiratory Distress Syndrome - premature infants 26 to 32 weeks
Phase 2a top-line data due July 2017.
Aerosurf
Respiratory Distress Syndrome - premature infants 26 to 28 weeks

Latest News

  1. Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial
  2. ETFs with exposure to Windtree Therapeutics, Inc. : May 22, 2017
  3. Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
  4. Windtree Therapeutics Reports First Quarter 2017 Financial Results and Provides Key Business Updates
  5. Windtree Receives Notice of Delisting from NASDAQ
  6. Windtree Therapeutics and Tonix Pharmaceuticals on the Rise after FDA Clinical Trial News
  7. Windtree Announces Successful Completion of Second and Final AEROSURF® Phase 2b Clinical Trial Interim Safety Review
  8. ETFs with exposure to Windtree Therapeutics, Inc. : April 7, 2017
  9. Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017
  10. Windtree Therapeutics Reports Fourth Quarter 2016 Financial Results and Provides Key Business Updates
  11. Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation and Improves Survival in a High-Pathogen Avian Influenza Preclinical Study
  12. Windtree Therapeutics to Host a Conference Call and Webcast at 8:00 AM on Thursday, February 16, 2017 to Provide Clinical and Financial Updates
  13. Windtree Therapeutics Completes $10.5 Million Private Offering
  14. ETFs with exposure to Windtree Therapeutics, Inc. : January 3, 2017
  15. Is Windtree Therapeutics Inc (WINT) Going to Burn These Hedge Funds?
  16. Windtree Therapeutics Announces Upcoming Presentations at Hot Topics in Neonatology
  17. Windtree Therapeutics' AEROSURF® (lucinactant for inhalation) Phase 2a Data Presented at the 2016 International Congress of Union of European Neonatal and Perinatal Societies
  18. Windtree Therapeutics to Present at Stifel 2016 Healthcare Conference
  19. Windtree Therapeutics Preclinical Study Results Show Potential for KL4 Surfactant as Possible Medical Countermeasure to Radiation Exposure
  20. Windtree Therapeutics to Host Conference Call and Webcast on Tuesday, October 25, 2016 to Provide a Business Update